文献速递炎症性肠病

单基因炎症性肠病异基因造血干细胞移植的结局

Outcomes of Allogeneic Hematopoietic Stem Cell Transplant in Monogenic Inflammatory Bowel Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-05-14

本研究为单中心回顾性研究,纳入2012至2022年在费城儿童医院接受造血干细胞移植的38例单基因炎症性肠病患儿,其中25例因炎症性肠病接受移植。中位随访3年时生存率100%,92%达到无药物持续缓解,生长、住院天数和严重感染均显著改善。

要点

  • 单基因炎症性肠病患儿移植后中位随访3年生存率100%。
  • 92%患儿达到无药物持续缓解,60%既往造口者完成还纳吻合。
  • 生长、住院天数和严重感染均显著改善。

核心结论

  • 造血干细胞移植可使单基因炎症性肠病患者达到无药物缓解并减少疾病相关并发症。
  • 对极早发型或难治性炎症性肠病患者进行基因评估并考虑造血干细胞移植具有重要意义,对免疫功能障碍相关单基因缺陷患者可能治愈并挽救生命。

研究设计与样本

  • 单中心回顾性研究,纳入2012至2022年在费城儿童医院接受造血干细胞移植的儿童单基因炎症性肠病患者。
  • 38例单基因炎症性肠病患者被确定符合造血干细胞移植条件,其中25例在研究期间因炎症性肠病接受造血干细胞移植。

主要发现

  • 中位随访3年时生存率为100%。
  • 移植前76%患者接受免疫抑制治疗,20%患者接受炎症性肠病相关手术。
  • 最近一次随访时,92%患者达到无药物持续缓解,60%既往有造口的患者完成还纳吻合。
  • 生长、住院天数和严重感染均有显著改善。

临床怎么用

  • 作者认为,对极早发型或难治性炎症性肠病患者应进行基因评估并考虑造血干细胞移植。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Monogenic inflammatory bowel disease (IBD) can result in inborn errors of immunity and intestinal epithelial cell dysfunction, more commonly seen in patients with very early onset IBD (VEO-IBD). Hematopoietic stem cell transplant (HSCT) has emerged as an effective treatment for a subset of patients with monogenic IBD. We sought to evaluate the efficacy and safety of HSCT in these patients. We hypothesized that HSCT will lead to IBD medication-free remission or significant improvement of disease. METHODS: This was a single-center, retrospective study of children with monogenic IBD who underwent HSCT at The Children's Hospital of Philadelphia from 2012 to 2022. The primary outcome was IBD medication-free sustained remission, measured by disease activity index. Secondary outcomes included all-cause mortality, growth, hospitalizations, infections, and HSCT-associated complications. RESULTS: Thirty-eight patients with monogenic IBD were identified as eligible for HSCT, with 25 undergoing HSCT as therapy for IBD during the study period. There was 100% survival at a median follow-up of 3 years. Prior to transplant, 76% of patients received immunosuppression, and 20% underwent IBD-related surgery. At most recent follow-up, 92% of patients achieved sustained medication-free remission of IBD and 60% with prior ostomy underwent re-anastomosis. There was significant improvement in growth, hospital days, and severe infections. CONCLUSIONS: HSCT resulted in IBD medication-free remission and reduction in disease-associated complications. This highlights the strength of genetic evaluation in patients with VEO-IBD or refractory IBD and consideration of HSCT, which can be curative and lifesaving in patients with monogenic defects involving immune dysfunction.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Baccarella A, Patel T, Conrad MA, et al. Outcomes of Allogeneic Hematopoietic Stem Cell Transplant in Monogenic Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2025. PMID: 40378986. doi:10.1016/j.cgh.2025.03.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。